Jonathan Scher, MD

Clinical Focus

• Cesarean Birth
• Heparin-Induced Thrombocytopenia
• Human Papillomavirus Vaccine
• Menopause
• Miscarriage
• Uterine Fibroids

• Cesarean Birth
• Heparin-Induced Thrombocytopenia
• Human Papillomavirus Vaccine
• Menopause
• Miscarriage
• Uterine Fibroids

Locations

Physician Office

1126 Park Avenue, New York, NY, 10128

212-427-7400

Insurance Information

Accepted insurance may vary by the doctor’s office location. Please contact the office directly to obtain the most up-to-date insurance information.

Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).

Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.

Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.

Publications

Article:23

Recent Artifacts

• Clinical experience with IVIg rx in patients with prior failed IVF pregnancies: Report of 30 consecutive patients
• Pregnancy loss in the antiphospholipid-antibody syndrome - A possible thrombogenic mechanism
• Prothrombin activation fragment (F1.2) is increased in pregnant patients with antiphospholipid antibodies
• Abstracts in reproductive immunology
• Antiphospholipid immunoglobulin G antibodies reduce annexin-V levels on syncytiotrophoblast apical membranes and in culture media of placental villi
• Correlation between karyotype and ultrasound findings in patients with failed early pregnancy
• Reduction of annexin-V (placental anticoagulant protein-I) on placental v ll of women with antiphospholipid antibodies and recurrent -spontaneous abortion
• Paternal Mononuclear Cell Immunization Therapy for Repeated Miscarriage: Predictive Variables for Pregnancy Success
• The incidence and outcome of asymptomatic herpes simplex genitalis in an obstetric population
• A new abortion technique: Intravaginal and intramuscular prostaglandin.

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Scher did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.